title: Strong control over multiple endpoints: are we adding value to the assessment of medicines?
authors.affiliation: AstraZeneca, Alderley Park, Macclesfield SK10 4TG, UK. Andrew.stone@astrazeneca.com
authors.forename: Andrew
authors.initials: A
authors.lastname: Stone
authors.forename: Christy
authors.initials: C
authors.lastname: Chuang-Stein
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends; D004348:Drug Labeling; D023381:Endpoint Determination / Q000379:methods* / Q000639:trends; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage
chemical_list: D004364:Pharmaceutical Preparations